source
- FDA approves Ionis’ Zanvastro as first disease-modifying therapy for Alexander diseaseThe U.S. Food and Drug Administration has granted approval to Ionis Pharmaceuticals' antisense oligonucleotide Zanvastro, the first therapy that modifies disease progression for Alexander disease.…
- Revolution Medicines' Rasonque shows 42% response and 16-month survival in NSCLC subgroupData from a subgroup of an earlier trial, described by Truist Securities as the most relevant to Revolution Medicines' ongoing Phase 3 study, reported a 42% overall response rate and a median overa…